ライフサイエンスコーパス: glucose-6-phosphate

1 ve and accumulates in the nucleus by sensing glucose 6-phosphate.

2 lyzes the phosphorylation of glucose to form glucose 6-phosphate.

3 bHK1 is not subject to inhibition by ADP and glucose 6-phosphate.

4 rythrose 4-phosphate, and with the substrate glucose 6-phosphate.

5 gh the conversion of glucose 1-phosphate and glucose 6-phosphate.

6 Xu5P = xylulose 5-phosphate, G6P = glucose 6-phosphate.

7 agy appears to be regulated by a decrease in glucose-6 phosphate.

8 d growth on minimal medium supplemented with glucose-6-phosphate.

9 nd secondary metabolism via the oxidation of glucose-6-phosphate.

10 concentrations of metabolites, particularly glucose-6-phosphate.

11 xin reductase (TrxR)1 cytoplasmic isoform 3, glucose-6-phosphate 1-dehydrogenase isoform a, Hsp105, v

12 dose reductase, thioredoxin reductase 1, and glucose-6-phosphate 1-dehydrogenase-were identified that

13 GM, Mg(2+)-phospho-beta-PGM, and Mg(2+)-beta-glucose-6-phosphate-1-phosphorane-beta-PGM complexes to

14 it partitions to form glucose 1-phosphate or glucose 6-phosphate 14.3 times more frequently than it d

15 nosamine from glucose-6-phosphate: NtdC is a glucose-6-phosphate 3-dehydrogenase, NtdA is a pyridoxal

16 he half-maximal activation concentration for glucose 6-phosphate (A(0.5)) was increased to 830 +/- 12

17 CcpA binding was enhanced upon addition of glucose-6-phosphate, a putative cofactor for CcpA.

18 orresponding to the basal activity state and glucose-6-phosphate activated state of yeast glycogen sy

19 d the incoming glucose producing the product glucose-6-phosphate, also at an elevated rate.

20 We observed a 2-fold elevation in glucose 6-phosphate and fructose 6-phosphate levels, whe

21 zyme, which catalyses the interconversion of glucose 6-phosphate and fructose 6-phosphate, has been s

22 alpha-D-glucopyranoside 6-phosphate to yield glucose 6-phosphate and methanol.

23 ited K(m) values of 0.57 mm and 8 microm for glucose 6-phosphate and NAD(+), respectively.

24 ficiency were associated with a reduction in glucose 6-phosphate and oleoyl-CoA levels, as well as a

25 cilitating enzyme-catalyzed oxidation of the glucose-6-phosphate and 6-phosphogluconate by NADP.

26 have identified dihydroxyacetone phosphate, glucose-6-phosphate and fructose-6-phosphate as addition

27 glycerate and 3-phosphoglycerate, as well as glucose-6-phosphate and fructose-6-phosphate.

28 ganded or bound to the competitive inhibitor glucose-6-phosphate and in the postcleavage state.

29 rylaldehyde-3-phosphate, ribose-5-phosphate, glucose-6-phosphate, and mannose-6-phosphate was achieve

30 mplished using isotopically labeled glucose, glucose-6-phosphate, and pyruvate as internal standards.

31 ase activity due to increased hexokinase II, glucose-6-phosphate, and RGL and PTG levels and enhanced

32 d-Glucose and d-glucose-6-phosphate are direct agonists of both LXR-alph

33 EBs preferentially used glucose-6-phosphate as an energy source, whereas RBs req

34 because it catalyses import into plastids of glucose-6-phosphate as the substrate for NADPH generatio

35 eaflet of mitochondria; however, the site of glucose 6-phosphate association responsible for the rele

36 PGI/PMI) has been determined in complex with glucose 6-phosphate at 1.16 A resolution and with fructo

37 esults here implicate a primary role for the glucose 6-phosphate binding site at the N-terminal half

38 In contrast, mutations that block glucose 6-phosphate binding to the N-terminal half requi

39 S is regulated by allosteric activation upon glucose-6-phosphate binding and inactivation by phosphor

40 on and activated by protein phosphatases and glucose-6-phosphate binding.

41 Finally, in addition to cyclic glucose 6-phosphate bound at the active site, the hexame

42 rmeable for glucose, glucose 1-phosphate and glucose 6-phosphate, but not for maltose.

43 -d-glucopyranose), which can be converted to glucose 6-phosphate by levoglucosan kinase (LGK).

44 It is synthesized from glucose 6-phosphate by myo-inositol-3-phosphate synthase

45 molecules closely related to GlcN6P, such as glucose-6-phosphate, cannot activate self-cleavage.

46 strates, including citric acid, formic acid, glucose 6-phosphate, capric acid, gamma-hydroxybutyric a

47 te (T6P) is synthesized from UDP-glucose and glucose-6-phosphate (catalyzed by T6P synthase [TPS]), a

48 e interconversion of glucose 1-phosphate and glucose 6-phosphate, catalyzed by Pseudomonas aeruginosa

49 ssociated with intracellular accumulation of glucose-6-phosphate caused by disruption of glycolytic f

50 have shown that a block in the metabolism of glucose 6-phosphate causes transient growth inhibition a

51 initiate glycolysis by converting glucose to glucose-6-phosphate, contains a strong PAR-binding motif

52 After UNSAT, but not CHO, muscle glucose-6-phosphate content was 103% higher compared wit

53 mice impairs allosteric activation of GS by glucose 6-phosphate, decreases hepatic glycogen synthesi

54 tatus of mitochondrial glutathione (GSH) and glucose 6-phosphate dehydrogenase (G6-PD) was restored b

55 Individuals with glucose 6-phosphate dehydrogenase (G6PD) deficiency are

56 Glucose 6-phosphate dehydrogenase (G6PD) is the most com

57 inactivating ATM or its downstream effector glucose 6-phosphate dehydrogenase (G6PD) sensitizes AML

58 eductant, NADPH by impairing the activity of glucose 6-phosphate dehydrogenase (G6PD).

59 , HDACi selectively enhance transcription of glucose 6-phosphate dehydrogenase (G6PD).

60 ant enzymes including alcohol dehydrogenase, glucose 6-phosphate dehydrogenase, glycerol 3-phosphate

61 e (70%), phosphoglucose isomerase (65%), and glucose-6-phosphate dehydrogenase (85%), but not phospho

62 a substrate for an enzyme, F(420)-dependent glucose-6-phosphate dehydrogenase (Fgd), found in few ba

63 ide transfer coenzyme for an F(420)-specific glucose-6-phosphate dehydrogenase (Fgd).

64 most commonly mediated by loss of a specific glucose-6-phosphate dehydrogenase (FGD1) or its deazafla

65 NADPH is produced by glucose-6-phosphate dehydrogenase (G-6-PDase) and 6-phos

66 -yl)-2,5-diphenyltetrazolium bromide] (MTT), glucose-6-phosphate dehydrogenase (G6DP), and calcein AM

67 ation and isocitrate dehydrogenase (IDH) and glucose-6-phosphate dehydrogenase (G6PD) activities are

68 riation in isocitrate dehydrogenase (IDH) or glucose-6-phosphate dehydrogenase (G6PD) activity in a s

69 Glucose-6-phosphate dehydrogenase (G6PD) activity is ess

70 ATM activation induces glucose-6-phosphate dehydrogenase (G6PD) activity, the l

71 ify cell death based upon the measurement of glucose-6-phosphate dehydrogenase (G6PD) activity.

72 Unexpectedly, Glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogl

73 d on the oxidation of G6P in the presence of glucose-6-phosphate dehydrogenase (G6PD) and nicotinamid

74 .-) production, suggesting that intranuclear glucose-6-phosphate dehydrogenase (G6PD) can control NOX

75 out dose-dependent haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deficiencies ha

76 ), alpha thalassaemia, ABO blood groups, and glucose-6-phosphate dehydrogenase (G6PD) deficiency enco

77 Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a

78 Glucose-6-phosphate dehydrogenase (G6PD) deficiency is b

79 Glucose-6-phosphate dehydrogenase (G6PD) deficiency is t

80 The global prevalence of X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency is t

81 Glucose-6-phosphate dehydrogenase (G6PD) deficiency is t

82 Glucose-6-phosphate dehydrogenase (G6PD) deficiency is t

83 omplicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

84 l malaria risk factors, and we also assessed glucose-6-phosphate dehydrogenase (G6PD) enzyme activity

85 The inhibition of glucose-6-phosphate dehydrogenase (G6PD) expression by a

86 s in mitochondria, whereas chloroquine and a glucose-6-phosphate dehydrogenase (G6PD) inhibitor affec

87 Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme

88 The gene coding for glucose-6-phosphate dehydrogenase (G6PD) is subject to p

89 The reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD) is the first, r

90 Glucose-6-phosphate dehydrogenase (G6PD) is the principa

91 Glucose-6-phosphate dehydrogenase (G6PD) is the rate-lim

92 The lipogenic enzyme glucose-6-phosphate dehydrogenase (G6PD) is unique in th

93 Glucose-6-phosphate dehydrogenase (G6PD) modulates vascu

94 hrough microscopy and had normal function of glucose-6-phosphate dehydrogenase (G6PD) on colorimetric

95 , which was exacerbated in erythrocytes from glucose-6-phosphate dehydrogenase (G6PD) patients and re

96 Glucose-6-phosphate dehydrogenase (G6PD) regulates produ

97 Glucose-6-phosphate dehydrogenase (G6PD) status was dete

98 In vivo, pharmacological inhibition of glucose-6-phosphate dehydrogenase (G6PD) to decrease NAD

99 t of reductive capacity by overexpression of glucose-6-phosphate dehydrogenase (G6PD), a key enzyme f

100 y (PPP) is necessary for NET release because glucose-6-phosphate dehydrogenase (G6PD), an important e

101 ented expression and enzymatic activities of glucose-6-phosphate dehydrogenase (G6PD), glutathione re

102 the bacterial pathogen Pseudomonas syringae Glucose-6-phosphate dehydrogenase (G6PD), the key enzyme

103 Glucose-6-phosphate dehydrogenase (G6PD), the rate-limit

104 Here we show that glucose-6-phosphate dehydrogenase (G6PD), the rate-limit

105 the activity of another cytoplasmic enzyme, glucose-6-phosphate dehydrogenase (G6PD), was also measu

106 ne deacetylase (HDAC) inhibitors (HDACis) in glucose-6-phosphate dehydrogenase (G6PD)-deficient cells

107 haemolysis in patients with a deficiency in glucose-6-phosphate dehydrogenase (G6PDd).

108 lucose uptake with a concomitant increase in glucose-6-phosphate dehydrogenase (G6PDH) activity, the

109 investigated the reactivation of aggregated glucose-6-phosphate dehydrogenase (G6PDH) by ClpB and it

110 Glucose-6-phosphate dehydrogenase (G6PDH) has been impli

111 toxification enzymes such as NQO1 as well as glucose-6-phosphate dehydrogenase (G6PDH), a regulator o

112 linked isocitrate dehydrogenase (NADP-ICDH), glucose-6-phosphate dehydrogenase (G6PDH), and, glutathi

113 showed here that a mutation in zwf, encoding glucose-6-phosphate dehydrogenase (G6PDH), leads to a ap

114 first and committed reaction is catalyzed by glucose-6-phosphate dehydrogenase (G6PDH).

115 We studied the contribution of glucose-6-phosphate dehydrogenase (Glc-6-PD), an importa

116 It is based on the glucose-6-phosphate dehydrogenase (Gpdh) and 6-phosphogl

117 compounds that inhibit Plasmodium falciparum glucose-6-phosphate dehydrogenase (PfG6PD).

118 ells grown on glucose has been attributed to glucose-6-phosphate dehydrogenase (Zwf1p) and a cytosoli

119 nal requirement mediating selection for high glucose-6-phosphate dehydrogenase activity.

120 Two NAD-dependent dehydrogenases (glucose-6-phosphate dehydrogenase and 6-phosphogluconate

121 cal NADPH homeostasis, which is regulated by glucose-6-phosphate dehydrogenase and AMP kinase.

122 ations involving conversion to N(tz) ADPH by glucose-6-phosphate dehydrogenase and reoxidation to N(t

123 Evaluations for glucose-6-phosphate dehydrogenase and thiopurine S-methy

124 A1 substantially reduced the inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal

125 as exemplified for the reaction catalyzed by glucose-6-phosphate dehydrogenase by comparing the 1-(13

126 acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd).

127 Other abnormal hemoglobins, glucose-6-phosphate dehydrogenase deficiency and pyruvat

128 [95% confidence interval {CI}, 0.52-0.90]), glucose-6-phosphate dehydrogenase deficiency in female c

129 Glucose-6-phosphate dehydrogenase deficiency serves as a

130 lpha-thalassemia, 0.3%; ABO group, 0.3%; and glucose-6-phosphate dehydrogenase deficiency, 0.5%) and

131 tors for neurotoxicity, such as prematurity, glucose-6-phosphate dehydrogenase deficiency, or hypoxia

132 t Asian ovalocytosis and two common forms of glucose-6-phosphate dehydrogenase deficiency.

133 Glucose-6-phosphate dehydrogenase deficient patients on

134 d sex-specific QTL underlying differences in glucose-6-phosphate dehydrogenase enzyme activity betwee

135 Patients with glucose-6-phosphate dehydrogenase enzyme activity of les

136 ith uncomplicated falciparum malaria, normal glucose-6-phosphate dehydrogenase enzyme levels, and hem

137 A large excess of ALDH3A1 also protected glucose-6-phosphate dehydrogenase from inactivation beca

138 hibition of the pentose phosphate pathway by glucose-6-phosphate dehydrogenase inhibitors and siRNA s

139 e did not observe changes in the activity of glucose-6-phosphate dehydrogenase or in the pentose phos

140 ococcal mutants deficient in PavA, CodY, and glucose-6-phosphate dehydrogenase pointing to the robust

141 METHODS AND Patients with normal glucose-6-phosphate dehydrogenase status with symptomati

142 ecific inhibitor (dehydroepiandrosterone) of glucose-6-phosphate dehydrogenase together established r

143 strain over-expressing zwf gene (coding for glucose-6-phosphate dehydrogenase), WX-zwf, produced the

144 The enzyme activities of glucose-6-phosphate dehydrogenase, 6-phosphogluconate de

145 blood cell polymorphisms (ie, hemoglobin S, glucose-6-phosphate dehydrogenase, and alpha-thalassemia

146 three enzymes (catechol-O-methyltransferase, glucose-6-phosphate dehydrogenase, and glyceraldehyde-3-

147 either 6PGD or another oxidative PPP enzyme, glucose-6-phosphate dehydrogenase, exhibit non-immune he

148 of the cytosolic isocitrate dehydrogenase or glucose-6-phosphate dehydrogenase, which also produce cy

149 ersensitivity to SFK2 yielded ZWF1, encoding glucose-6-phosphate dehydrogenase, which has been shown

150 In P. falciparum , the bifunctional enzyme glucose-6-phosphate dehydrogenase-6-phosphogluconolacton

151 oncomitant inhibition of the parasite enzyme glucose-6-phosphate dehydrogenase-6-phosphogluconolacton

152 Conditional expression of the glucose-6-phosphate dehydrogenase-encoding gene zwf, sho

153 sses hexokinase and the rate-limiting enzyme glucose-6-phosphate dehydrogenase.

154 aemia, and a mutation of G6PD, which encodes glucose-6-phosphate dehydrogenase.

155 ence of 6-aminonicotinamide, an inhibitor of glucose-6-phosphate dehydrogenase.

156 ntapeptide derived from the metabolic enzyme glucose-6-phosphate dehydrogenase.

157 red lactate dehydrogenase and heat-denatured glucose-6-phosphate dehydrogenase.

158 r non-specific glycolytic proteins such as d-glucose-6-phosphate dehydrogenase.

159 In addition, glucose-6-phosphate-dehydrogenase (G6PD) deficiency, whi

160 No correlation with sickle cell trait or glucose-6-phosphate-dehydrogenase deficiency was observe

161 xis to induce expression of hexokinase (HK), glucose-6-phosphate dehyrogenase (G6PD) and pyruvate kin

162 osteric activators (fructose-6-phosphate and glucose-6-phosphate) did not always mimic the changes ob

163 petent to form either glucose 1-phosphate or glucose 6-phosphate directly.

164 the isomerization of fructose-6-phosphate to glucose-6-phosphate (F6P --> G6P) by baker's yeast phosp

165 ic glucose production by failing to redirect glucose-6-phosphate flux from production of glucose to g

166 and mutant hexokinases from mitochondria by glucose 6-phosphate follow equilibrium models, which exp

167 pproximately 7-fold higher concentrations of glucose 6-phosphate for the release of HKI.

168 Diabetes elevated glucose 6-phosphate, fructose 6-phosphate and oxidised (

169 I) and phosphoglucose mutase interconverting glucose 6-phosphate, fructose 6-phosphate, and glucose 1

170 sphate and sedoheptulose 1-phosphate but not glucose 6-phosphate, fructose 6-phosphate, and sedoheptu

171 Glucose 6-phosphate (G-6P), a product of the catalytic a

172 synthase (mIPS) catalyzes the conversion of glucose-6-phosphate (G-6-P) to inositol-1-phosphate.

173 phosphocreatine (PCr) turnover but increased glucose-6-phosphate (G-6-P) turnover, glucose utilizatio

174 , in general, glucose metabolism at least to glucose-6-phosphate (G-6-P).

175 ccomplished by the small molecule effectors, glucose 6-phosphate (G6P) and fructose 1,6-bisphosphate

176 Glucose 6-phosphate (G6P) is a metabolic intermediate wi

177 se-6-phosphatase catalyzes the hydrolysis of glucose 6-phosphate (G6P) to glucose and inorganic phosp

178 ion of beta-glucose 1-phosphate (betaG1P) to glucose 6-phosphate (G6P) using Asp8 of the core domain

179 beta-D-glucose 1-phosphate (betaG1P) into D-glucose 6-phosphate (G6P) via sequential phosphoryl tran

180 -d-glucose 1-phosphate (beta-G1P) and beta-d-glucose 6-phosphate (G6P), forming beta-d-glucose 1,6-(b

181 ate (betaG1P) derived from maltose to beta-d-glucose 6-phosphate (G6P).

182 x interplay between the allosteric activator glucose-6-phosphate (G6P) and reversible phosphorylation

183 Based on the reaction of glucose-6-phosphate (G6P) and the diaphorase-resazurin a

184 acterium tuberculosis (Mtb) PYK uses AMP and glucose-6-phosphate (G6P) as synergistic allosteric acti

185 Insulin reduced gluconeogenic flux to glucose-6-phosphate (G6P) but only at the near-maximal p

186 G6PT translocates glucose-6-phosphate (G6P) from the cytoplasm into the lu

187 se-beta (G6Pase-beta or G6PC3) that converts glucose-6-phosphate (G6P) into glucose, the primary ener

188 gluconeogenesis and glycogenolysis, in which glucose-6-phosphate (G6P) is hydrolyzed to glucose for r

189 Consistent with a glucose-6-phosphate (G6P) metabolism deficiency, G6pc3(-

190 Tps1 integrates glucose-6-phosphate (G6P) metabolism with nitrogen sourc

191 a like Escherichia coli, the accumulation of glucose-6-phosphate (G6P) or its analogs such as alpha-m

192 d previously that increased carbon flux from glucose-6-phosphate (G6P) through the pentose phosphate

193 se-6-phosphatase catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose and inorganic phosp

194 alpha (G6Pase-alpha or G6PC) that hydrolyzes glucose-6-phosphate (G6P) to glucose.

195 Ib (GSD-Ib) is caused by deficiencies in the glucose-6-phosphate (G6P) transporter (G6PT) that have b

196 Ib (GSD-Ib) is caused by a deficiency in the glucose-6-phosphate (G6P) transporter (G6PT) that works

197 meostasis resulting from a deficiency in the glucose-6-phosphate (G6P) transporter (G6PT).

198 colorimetric assay for the determination of glucose-6-phosphate (G6P) was developed.

199 sphates, such as glycerol-3-phosphate (G3P), glucose-6-phosphate (G6P), and fosfomycin.

200 t (Arg582Ala) that could not be activated by glucose-6-phosphate (G6P), but possessed full catalytic

201 e (2-DG), iodoacetate (IAA)), intermediates (glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), f

202 in secretion (GSIS) that acts by hydrolyzing glucose-6-phosphate (G6P), thereby reducing glycolytic f

203 se enzymes catalyze conversion of glucose to glucose-6-phosphate (G6P), which is the first step in th

204 ine, fructose, glucose, glucose-1-phosphate, glucose-6-phosphate, galactose, lactose, and sucrose--at

205 e kinase that is allosterically activated by glucose 6-phosphate (Glc-6-P) and adenosine monophosphat

206 During glucose 6-phosphate (Glc-6-P) hydrolysis, Glc-6-Pase-alp

207 final steps of glycogenolysis, intracellular glucose 6-phosphate (Glc-6-P) is transported into the en

208 and isomerization for the interconversion of glucose 6-phosphate (Glc-6-P) to fructose 6-phosphate (F

209 e allosteric inhibition of E. coli FBPase by glucose 6-phosphate (Glc-6-P), the first metabolite prod

210 generated between meals by the hydrolysis of glucose-6-phosphate (Glc-6-P) in the liver and the kidne

211 nd with the cofactor GlcN6P or the inhibitor glucose 6-phosphate (Glc6P) at 1.7 A and 2.2 A resolutio

212 me bound to a naturally occurring inhibitor, glucose 6-phosphate (Glc6P), and a nonnatural activating

213 tdA is a pyridoxal phosphate-dependent 3-oxo-glucose-6-phosphate:glutamate aminotransferase, and NtdB

214 were responsible for generating two NADH per glucose-6-phosphate (i.e., four electrons were generated

215 ehyde-3-phosphate, fructose-6-phosphate, and glucose-6-phosphate; (ii) has smaller cells (diameter ca

216 Analyses of free glucose and glucose 6-phosphate in milk have until now been dependen

217 k that was stripped of intrinsic glucose and glucose 6-phosphate in order to obtain standards and sam

218 tes glucose homeostasis, converts glucose to glucose-6-phosphate in pancreatic beta-cells, liver hepa

219 hosphate, as well as glucose 1-phosphate and glucose 6-phosphate, in vitro.

220 One molecule of glucose 6-phosphate inhibits brain hexokinase (HKI) with

221 the structure of mIPS with a trapped 5-keto-glucose-6-phosphate intermediate at 2 A resolution by a

222 combination with conversion of the formed d-glucose-6-phosphate into mixtures of labeled methyl d-gl

223 poptosis (TIGAR), which promotes shunting of glucose-6-phosphate into the pentose phosphate pathway t

224 T2 expression by Suc increases the import of glucose-6-phosphate into the plastids that would repress

225 zyme-catalyzed phosphorylation of glucose to glucose-6-phosphate is a reaction central to the metabol

226 we demonstrate that the enzyme's response to glucose-6-phosphate is controlled by Arg583 and Arg587,

227 Glucose-6-phosphate is extensively degraded by the OPP p

228 6.TCR.Calpha(-/-)H-2(b/g7) mice induced anti-glucose 6-phosphate isomerase antibody-dependent chronic

229 y passive transfer of autoantibodies against glucose 6-phosphate isomerase is transient and therefore

230 elping B cells to produce arthritogenic anti-glucose-6-phosphate isomerase (anti-GPI) autoantibodies.

231 atoid arthritis, autoantibodies specific for glucose-6-phosphate isomerase (GPI) can transfer joint-s

232 Glucose-6-phosphate isomerase (GPI) is the target autoan

233 ceptors (BCRs) with different affinities for glucose-6-phosphate isomerase (GPI) were examined in the

234 vealed a point mutation, Gly-189 --> Glu, in glucose-6-phosphate isomerase (GPI), a glycolytic enzyme

235 high titers of antibodies against the enzyme glucose-6-phosphate isomerase (GPI), promoted by CD4(+)

236 autoimmune arthritis by tracking the fate of glucose-6-phosphate isomerase (GPI)-reactive CD4(+) T ce

237 Immunization with human glucose-6-phosphate isomerase (hG6PI) protein or with se

238 thal phenotype of RNAi-mediated depletion of glucose-6-phosphate isomerase (PGI) in the glucose-deple

239 tive pentose phosphate (OPP) pathway and the glucose-6-phosphate isomerase (PGI) reaction.

240 Finally, two proteins (glucose-6-phosphate isomerase [EC 5.3.1.9] and isoflavon

241 se and reduced deposition of pathogenic anti-glucose-6-phosphate isomerase Abs in the joint (with a r

242 r domain serves as a scaffold for recruiting glucose-6-phosphate isomerase and dehydrogenase.

243 inefficient at taking up the key autoantigen glucose-6-phosphate isomerase and that Msr1-deficient mi

244 uld not be reproduced by increasing the anti-glucose-6-phosphate isomerase antibody load, which demon

245 mber of the IL-1 family, can exacerbate anti-glucose-6-phosphate isomerase autoantibody-induced arthr

246 e model of arthritis, autoantibodies against glucose-6-phosphate isomerase cause joint-specific infla

247 osure, twice-a-day treatment with 17l in the glucose-6-phosphate isomerase chronic in vivo mouse mode

248 (2) died in galactose medium as well as when glucose-6-phosphate isomerase was knocked down, suggesti

249 to [6,6'-(3)H]Fru-2,6-P(2) using hexokinase, glucose-6-phosphate isomerase, and 6-phosphofructo-2-kin

250 ormation and autoantibody production against glucose-6-phosphate isomerase, leading to joint inflamma

251 e in the titer of serum antibodies targeting glucose-6-phosphate isomerase, the relevant autoantigen,

252 ransgenic mice specific for the self-antigen glucose-6-phosphate isomerase, we show that autoreactive

253 icro-positron emission tomography that these glucose-6-phosphate isomerase-specific autoantibodies ra

254 Glucose-6-phosphate isomerase-specific plasma cells did

255 nt mice had elevated serum concentrations of glucose-6-phosphate isomerase.

256 thritis is induced by autoantibodies against glucose-6-phosphate-isomerase (GPI).

257 .5 +/- 0.5 %ID/g), as early as 1 d after the glucose-6-phosphate-isomerase serum injection, a time po

258 We injected mice with serum containing glucose-6-phosphate-isomerase-specific antibodies to ind

259 nalogous to the Entner-Doudoroff pathway for glucose-6-phosphate: It involves an NAD(+)-dependent SQ

260 tes, this regulation is accomplished through glucose-6-phosphate levels and protein phosphorylation.

261 patic glucose production and reduces hepatic glucose-6-phosphate levels to complete a homeostatic loo

262 ding to an approximately twofold increase in glucose-6-phosphate levels.

263 -> UDP-glucose <--> glucose 1-phosphate <--> glucose 6-phosphate <--> fructose 6-phosphate, showed a

264 nd glucose uptake determined through 2-deoxy glucose 6 phosphate luminescence.

265 pathway suggests that in addition to sensing glucose 6-phosphate, MondoA can also sense glucosamine 6

266 catalyze the biosynthesis of kanosamine from glucose-6-phosphate: NtdC is a glucose-6-phosphate 3-deh

267 sitol is generated by de novo synthesis from glucose 6-phosphate or is provided from the environment

268 Some bacteria experience stress when glucose-6-phosphate or analogues like alpha-methyl gluco

269 Glucose-6-phosphate phosphatase, catalyzing the final me

270 The glucose-6-phosphate/phosphate antiporter GPT1 is a major

271 ADP-dependent glucokinase (ADPGK) catalyzes glucose-6-phosphate production, utilizing ADP as a phosp

272 half of HKI have little or no effect on the glucose 6-phosphate release.

273 In addition to potent inhibition, glucose 6-phosphate releases HKI from the outer leaflet

274 ing isolated intact liver or fat microsomes, glucose-6 phosphate stimulated 11 beta-HSD1 oxo-reductas

275 n storage phenotype by genetic inhibition of glucose-6-phosphate-stimulated glycogen synthase activit

276 lator of basal GSIS that acts by hydrolyzing glucose-6-phosphate, thereby reducing glycolytic flux.

277 P-glucuronate) stemmed from UDP-glucose, not glucose 6-phosphate; therefore, UDP-glucuronate arose pr

278 The encoded 62-kDa human enzyme converted d-glucose 6-phosphate to 1-d-myo-inositol 3-phosphate, the

279 he de novo synthesis is the isomerization of glucose 6-phosphate to 1-D-myo-inositol-3-phosphate, cat

280 t equatorial transamination of 3-oxo-alpha-D-glucose 6-phosphate to form alpha-D-kanosamine 6-phospha

281 Mutations that block the binding of glucose 6-phosphate to the C-terminal half of HKI have l

282 G-6-Pase) catalyzes the dephosphorylation of glucose-6-phosphate to glucose, an opposite process to g

283 synthase (MIPS) catalyzes the conversion of glucose-6-phosphate to myo-inositol-1-phosphate.

284 template and 2), evolutionary homology using glucose-6-phosphate translocase as a template.

285 ffect was blocked by selective inhibitors of glucose-6-phosphate transport.

286 y a deficiency in the ubiquitously expressed glucose 6-phosphate transporter (Glc-6-PT).

287 ense oligonucleotides (ASOs) specific to the glucose 6-phosphate transporter-1 (G6PT1) enabled reduct

288 e disease type-Ib (GSD-Ib), deficient in the glucose-6-phosphate transporter (G6PT), is characterized

289 by a deficiency in a ubiquitously expressed glucose-6-phosphate transporter (G6PT).

290 tid, on the one hand, and up-regulation of a GLUCOSE-6-PHOSPHATE TRANSPORTER (GPT2), on the other han

291 omal-recessive disease caused by mutation of glucose-6-phosphate transporter and characterized by alt

292 this question, we investigated the effect of glucose-6-phosphate transporter mutation on immune cell

293 gh the study of neutrophils deficient in the glucose-6-phosphate transporter, describe a novel role f

294 olyphosphate glucokinase converts glucose to glucose-6-phosphate using low-cost, stable polyphosphate

295 he postulated competing pathway leading from glucose 6-phosphate via myo-inositol.

296 e values of K(m) for glucose-1-phosphate and glucose-6-phosphate were determined using the substrate-

297 it interface is rearranged by the binding of glucose-6-phosphate, which frees the active site cleft a

298 supplementation of Xenopus egg extract with glucose-6-phosphate, which promotes caspase-2/14-3-3zeta

299 ion, glucose 1,6-bisphosphate is formed from glucose 6-phosphate with a rate constant of 12 s(-)(1),

300 iauxic growth on glucose/lactose and glucose/glucose-6-phosphate with that of the individual models.